Andrew Bradbury

Andrew Bradbury is the Founder and Chief Scientific Officer of Specifica, a Q² Solutions Company, where responsibilities include the development of therapeutic antibodies using the Generation 3 platform, which produces high-affinity, drug-like antibodies from naïve libraries. Prior to founding Specifica in June 2016, Andrew served as Group Leader and Research Scientist at Los Alamos National Laboratory (LANL) from 1999 to 2017. Andrew's academic background includes a Doctor of Philosophy in Molecular Immunology from the University of Cambridge, a Bachelor of Medicine and Bachelor of Surgery from Guy's Hospital, London University, and a Bachelor of Arts in Physiological Sciences/Medicine from the University of Oxford.